New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
08:15 EDTQLTIQLT Inc. decided to independently develop QLT091001 after review
QLT Inc. issued a letter to its shareholders outlining the company's recent progress and its 2013 objectives. QLT said expects its recently augmented Synthetic Oral Retinoid leadership team to meet with the FDA by the end of Q1 2013 to discuss the most prudent development path to advance QLT091001. Until the aforementioned FDA meeting is concluded, QLT does not expect to provide timelines for potential pivotal trial initiation. The company added that after evaluating the strategic options available to enhance shareholder value with respect to its Synthetic Oral Retinoid program, the board has determined at this time that independently developing QLT091001 is the most value enhancing path forward for QLT shareholders. Also, QLT reiterated its commitment to return both a significant and appropriate amount of capital to shareholders in the near term. The company's board said it hopes to be able to complete all or a significant portion of its return of capital program in the first half of 2013.
News For QLTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
18:46 EDTQLTIQLT Inc. says InSite has received second unsolicited offer
Subscribe for More Information
August 27, 2015
08:37 EDTQLTIQLT Inc., InSite Vision agree on amended, restated merger agreement
Subscribe for More Information
08:31 EDTQLTIInsite Vision, QLT amend merger agreement
Subscribe for More Information
August 21, 2015
08:44 EDTQLTIQLT Inc. provides update on proposed acquisition of InSite Vision
QLT Inc. announces that it has been advised by InSite Vision that the board of InSite has determined in good faith after consultation with its independent financial and legal advisors that the previously announced unsolicited offer from a multi-national pharmaceutical company to acquire all of the issued and outstanding shares of InSite constitutes a "Company Superior Proposal" as defined in the Agreement and Plan of Merger, dated June 8, by and among Insite, QLT and Isotope Acquisition Corp., as amended and restated. InSite has further advised QLT that InSite intends, subject to QLT's right to match the Proposal, to terminate the Merger Agreement and enter into an agreement with the Bidder to implement the Proposal. Under the Merger Agreement, QLT has the option until 5:00 p.m. PDT on Wednesday, August 26, to negotiate a possible amendment to the terms of the Merger Agreement to match or exceed the Proposal. InSite has advised QLT that it intends to negotiate in good faith with QLT during the Negotiation Period. If at the end of the Negotiation Period such amended QLT proposal results in the Proposal not being a "Company Superior Proposal" under the Merger Agreement, InSite and QLT will enter into an agreement to reflect the amended terms of the transaction. In the event that QLT elects not to match or exceed the Proposal and if InSite terminates the Merger Agreement in order to enter into an agreement with the Bidder, then InSite is required to pay a termination fee to QLT in the amount of $1.17M. QLT is considering its position with respect to the Proposal and its matching right, and will keep the market apprised of further developments.
08:31 EDTQLTIInSite Vision says unsolicted offer a 'company superior proposal'
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use